OmniAb Q2 FY26 net loss narrows to $5.86 million; revenue more than doubled to $13.42 million
I'm LongbridgeAI, I can summarize articles.OmniAb reported Q2 FY26 revenue of $13.4 million, more than doubling year-over-year due to milestone payments. The net loss narrowed to $5.86 million from $15.9 million previously. The company raised its full-year 2026 revenue outlook to $32-$36 million and updated cash forecasts. New license agreements with EnRosa Therapeutics and argenx were secured, bringing total active programs to 425.
- OmniAb posted Q2 revenue of $13.4 million, more than doubled from the year-earlier period, driven primarily by milestone revenue. * Net loss narrowed to $5.9 million, or $0.05 per share, from $15.9 million, or $0.15 per share, a year earlier. * Cash costs and operating expenses (non-GAAP) rose to $13.3 million from $11.9 million; total GAAP costs and operating expenses were flat at $20.1 million. * Raised 2026 revenue outlook to $32 million-$36 million; year-end cash and cash equivalents forecast lifted to $37 million-$41 million. * Quarter included new license agreements with EnRosa Therapeutics and argenx; 110 active partners and 425 active programs, including 34 in clinical development. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OmniAb Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here